IMAGING
Centre for Probe Development and Commercialization

MISSION AND EXPERTISE

The Centre for Probe Development and Commercialization (CPDC) discovers, develops, and distributes molecular imaging probes using its deep expertise in radiopharmaceuticals. Founded in 2008 as a Centre of Excellence for Commercialization and Research (CECR), CPDC specializes in radiopharmaceutical research and development, and was created to assist Canadian and international academic and industry leaders with the advancement of new agents and radiotherapeutics into clinical trials. It also is mandated to increase physician access to new, cutting-edge radiopharmaceuticals, thereby benefitting patients throughout Canada. The CPDC has gained recognition as a leading radiopharmaceutical organization and its staff has the full range of scientific, technical, regulatory and business expertise required for translation of novel radiopharmaceuticals to the clinic, and to support the clinical supply of those agents.

CAPABILITIES

Our goals are to help both our academic and pharma partners assess and de-risk their pharmaceutical assets, and to assist them through the translational research gap by providing them with the collaborative support they need. This includes all areas of radiopharmaceutical R&D, process development and manufacturing, quality assurance, regulatory affairs and business development. We work with our partners to assess and fully understand the scientific and technical aspects of their research and product development programs, and to interlace this understanding with the cogent regulatory and business objectives.

TRACK RECORD

Working with our academic and pharma partners, which include our joint ventures with University Health Network (UHN), CanProbe, and our collaboration at the Ottawa Heart Institute, CPDC has completed over 50 radiopharmaceutical discovery, development, and manufacturing programs. We have moved 17 different radiopharmaceuticals into clinical development, which currently support more than 25 clinical trials. The CPDC's GMP quality management system has been audited eight times by health authorities (Health Canada and the U.S. Food and Drug Administration) and nine times by commercial clients and has consistently received a compliant rating.

We have partnered with clinical colleagues to enable the utilization of important molecular imaging biomarkers developed in basic research programs. Thus, clinical trials in the areas of hypoxia, cellular proliferation, prostate-specific membrane antigen expression, amyloid accumulation, choline uptake, and bone metabolism have benefitted from research tracers manufactured by the CPDC. Through CanProbe we have recently collaborated with UHN to provide [Ga-68]-DOTATATE and [Lu-177]-DOTATATE for an Ontario-based clinical trial, funded by Cancer Care Ontario, which will expand the access of these important radiopharmaceuticals to Ontario patients with neuroendocrine tumours.

CONTACT INFORMATION

TECHNOLOGY SUB-PROGRAM INSTITUTION:	Centre for Probe Development and Commercialization McMaster University 1280 Main St. W. , Hamilton, ON, L8S 4K1
PROGRAM LEADER(S):	**John F. Valiant** | 905-525-9140 x20182
PROGRAM MANAGER:	**Lynn Wick** | 905-529-9140 x26882

Ontario

Funding for OICR is provided by the Government of Ontario